Syncom Formulations India Share Price Target 2027: 20.3% Upside to Rs 24.3, Bull Rs 29.2

Investors weighing a Syncom Formulations India target price for 2027 should start with where the stock sits today. At Rs 20.20 on 13 November 2026, it is 26.5% below its 52-week high of Rs 27.49 and 97.8% above its 52-week low of Rs 10.21. That range spans 169% from low to high, so the entry point matters as much as the Syncom Formulations India price forecast itself.

This article builds the Syncom Formulations India share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Syncom Formulations India Stock Analysis: Company Overview and Key Stats

Syncom Formulations India (NSE: SYNCOMF) has a market capitalisation of Rs 1,904 crore. In FY26 it reported revenue of Rs 520.51 crore and net profit of Rs 76.44 crore. The table collects the figures the Syncom Formulations India share price target is built on.

Metric	Value
Company	Syncom Formulations India
NSE Ticker	SYNCOMF
CMP (13 November 2026)	Rs 20.20
52-Week High	Rs 27.49
52-Week Low	Rs 10.21
Market Cap	Rs 1,904 crore
PE Ratio (TTM)	22.26
Industry PE	40.55
Price to Book	4.59
Return on Equity	18.42%
Debt to Equity	0.00
EPS (TTM)	Rs 0.91
Dividend Yield	0.49%
12-Month Base Target	Rs 24.3
Bull Case	Rs 29.2
Downside Risk Level (not a target)	Rs 16.2

Why Is Syncom Formulations India Share Price Target Set at Rs 24.3 for 2027?

The arithmetic is short. Trailing EPS of Rs 0.91 grown for one year gives a forward EPS estimate of Rs 1.09, and multiplying it by the unchanged PE of 22.26 gives the Rs 24.3 base-case Syncom Formulations India stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Syncom Formulations India Target Price: Five Years of Results

Syncom Formulations India grew revenue from Rs 231.66 crore in FY22 to Rs 520.51 crore in FY26, a compound annual growth rate of 22.4%. Net profit grew faster, from Rs 19.79 crore to Rs 76.44 crore (40.2% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	231.66	19.79	0.24	0.03
FY23	238.85	20.07	0.24	0.00
FY24	276.91	25.31	0.34	0.00
FY25	482.45	49.43	0.53	0.00
FY26	520.51	76.44	0.81	0.10

FY26 revenue growth was 7.9%, slower than the four-year average of 22.4%, and net profit moved up 54.6%. EPS rose from Rs 0.34 in FY24 to Rs 0.81 in FY26. The FY27 outlook for the Syncom Formulations India price target depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Syncom Formulations India converted 14.7% of FY26 revenue into net profit, against 10.2% in FY25, within a five-year range of 8.4% to 14.7%. EBITDA margin was 20.9% in FY26 versus 14.8% in FY25.

In the June 2026 quarter, revenue was Rs 133.36 crore, up 8.5% from the same quarter a year earlier, while net profit of Rs 24.85 crore was up 57.8%. EBITDA came in at Rs 34.04 crore, up 55.9% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Syncom Formulations India stock target holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.00, and shareholders' equity grew from Rs 222.22 crore in FY22 to Rs 414.99 crore in FY26. Operating cash flow in FY26 was Rs 58.08 crore against capital expenditure of Rs 11.67 crore, leaving free cash flow of Rs 46.41 crore, or 2.4% of the current market capitalisation. In FY25 free cash flow was Rs 13.48 crore.

Valuation Check for the Syncom Formulations India Stock Target: PE, Price to Book and ROE

At a PE of 22.26 against an industry PE of 40.55, Syncom Formulations India trades at a discount to its industry. Price to book is 4.59 on a book value of Rs 4.41 per share, and return on equity is 18.42%. A PE of 22.26 equals an earnings yield of 4.5%, and the FY26 dividend of Rs 0.10 per share gives a yield of 0.49%.

Shareholding Pattern and Institutional Holding

Promoters held 50.57% of Syncom Formulations India in September 2026, and promoter holding has stayed near 50.57% since September 2025. Foreign institutional investors (FII) held 2.22% and domestic institutions (DII) held 0.00%, which puts total institutional holding at 2.22%. FII holding rose from 0.10% in September 2025 to 2.22% in September 2026. Public shareholders own the remaining 47.20%. Institutional holding this low means the stock sees limited professional coverage, and price moves can be sharper when trading volumes are thin.

Syncom Formulations India Share Price Targets for the Short Term and 12 Months

Short Term Syncom Formulations India Stock Target Levels: Technical Setup

At Rs 20.20 on 13 November 2026, Syncom Formulations India trades below its 50-day simple moving average of Rs 21.11 and above its 200-day exponential moving average of Rs 17.23. The 14-day RSI reads 50.7, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 21.11 (50-day simple moving average) and the nearest support is Rs 17.23 (200-day exponential moving average). A sustained move above Rs 21.11 would improve the short-term setup, while a close below Rs 17.23 would shift attention to the next support.

12 Month Syncom Formulations India Target Price for 2027

The 12-month target of Rs 24.3 means a move of 20.3% up from Rs 20.20 over the next 12 months. It would still leave the stock 11.6% below its 52-week high of Rs 27.49. Anyone checking the Syncom Formulations India share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.

How EPS Growth and PE Multiple Change the Syncom Formulations India Target Price

EPS Growth	PE 17.81	PE 22.26	PE 25.60
0.0% (EPS Rs 0.91)	Rs 16.2	Rs 20.3	Rs 23.3
20.0% (EPS Rs 1.09)	Rs 19.4	Rs 24.3	Rs 27.9
25.0% (EPS Rs 1.14)	Rs 20.3	Rs 25.4	Rs 29.2

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Syncom Formulations India price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Syncom Formulations India Stock Target in 2027

Bull Case Rs 29.2

The bull case Syncom Formulations India price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 1.14, and a PE multiple that rises 15% to 25.60. That gives Rs 29.2, 44.6% above the current price and above the 52-week high of Rs 27.49, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 16.2

The downside risk level is not a target. It assumes EPS stays flat at Rs 0.91 and the PE falls 20% to 17.81. That gives Rs 16.2, 19.8% below the current price and above the 52-week low of Rs 10.21.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	25.0%	25.60	Rs 29.2	+44.6%
Base Case	20.0%	22.26	Rs 24.3	+20.3%
Downside Risk	0.0%	17.81	Rs 16.2	-19.8%

Key Risks to the Syncom Formulations India Target Price for 2027

Growth Slowdown Risk for the Syncom Formulations India Price Target

Revenue in the June 2026 quarter was up 8.5% year on year, and FY26 revenue growth was 7.9%. If growth slows from here, the EPS estimate behind the Syncom Formulations India stock target will need revising.

Liquidity and Size Risk

Syncom Formulations India has a market capitalisation of Rs 1,904 crore. Institutional holding is 2.22%, and promoters hold 50.57%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 14.7% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 22.26 versus an industry PE of 40.55, a de-rating toward the downside-risk PE of 17.81 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 50.7 and the MACD sits below its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.

How to Invest in Syncom Formulations India

Start with the live price and volume. Any Syncom Formulations India share price target is only as current as the data behind it, and the data here is as of 13 November 2026, so refresh the Rs 20.20 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Syncom Formulations India's PE, ROE, debt and shareholding in one place.

Check Syncom Formulations India fundamentals on the Univest Screener

Then compare the three Syncom Formulations India target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Syncom Formulations India live price and get daily stock recommendations.

Conclusion

The Syncom Formulations India share price target for 2027 is Rs 24.3 in the base case, with Rs 29.2 as the bull case. The support for that view is arithmetic you can check: EPS grew 54.3% a year over FY24 to FY26, and the stock trades at a PE of 22.26. The risks are equally concrete, including institutional holding of only 2.22% and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Syncom Formulations India price target, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Syncom Formulations India Share Price Target 2027

What is the Syncom Formulations India share price target for 2027?

Ans. The base-case Syncom Formulations India share price target for 2027 is Rs 24.3, which is 20.3% above the price of Rs 20.20 on 13 November 2026. The bull case is Rs 29.2 and the downside risk level, which is not a target, is Rs 16.2. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Syncom Formulations India share price today?

Ans. As of 13 November 2026, 9:21 AM IST, Syncom Formulations India (NSE: SYNCOMF) trades at Rs 20.20, down 0.20% on the day. That is 26.5% below the 52-week high of Rs 27.49 and 97.8% above the 52-week low of Rs 10.21. The market capitalisation of Rs 1,904 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Syncom Formulations India a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 54.3% a year over FY24 to FY26 and the base case implies 20.3% upside; on the cautious side, institutional holding is only 2.22%, and the downside risk level of Rs 16.2 is 20% below the current price. Whether Syncom Formulations India fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Syncom Formulations India shares?

Ans. The bull case in the Syncom Formulations India share price target for 2027 is Rs 29.2, which assumes 25.0% EPS growth and a PE of 25.60, a 15% re-rating from today's multiple. That is 44.6% above the current price and above the 52-week high of Rs 27.49, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 16.2, which assumes flat EPS and a PE of 17.81, 20% lower than today. It sits 19.8% below the current price and above the 52-week low of Rs 10.21, and it marks a risk to watch, not a target.

What are the main risks to the Syncom Formulations India price target?

Ans. Four risks matter most for the Syncom Formulations India share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 1,904 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 17.81 would cut the price even if earnings hold.

What is the PE ratio of Syncom Formulations India and how does it compare with the industry?

Ans. The PE ratio of Syncom Formulations India is 22.26, against an industry PE of 40.55, which is a discount to the industry. Price to book is 4.59 and return on equity is 18.42%, and the PE equals an earnings yield of 4.5%. The base case holds the PE unchanged, so the Syncom Formulations India share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Syncom Formulations India, and what is the promoter holding?

Ans. Promoters held 50.57% of Syncom Formulations India in September 2026. FII held 2.22%, DII held 0.00% and the public held 47.20%. Together the two institutional groups hold 2.22%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Syncom Formulations India's latest quarterly results?

Ans. In the June 2026 quarter, Syncom Formulations India reported revenue of Rs 133.36 crore (up 8.5% year on year) and net profit of Rs 24.85 crore (up 57.8%). For comparison, FY26 full-year revenue growth was 7.9% and net profit moved up 54.6%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.